Rachid Izzar's Insider Trades & SAST Disclosures
Rachid Izzar's most recent trade in Biogen Inc was a trade of 1,515 Common Stock done . Disclosure was reported to the exchange on Feb. 10, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Rachid Izzar.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Biogen Inc | Rachid Izzar | Head of Global Product Strat. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Feb 2025 | 1,515 | 8,998 (0%) | 0% | 0 | Common Stock | |
| Biogen Inc | Rachid Izzar | Head of Global Product Strat. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Feb 2025 | 1,515 | 0 | - | - | Restricted Stock Unit | |
| Biogen Inc | Rachid Izzar | Head of Global Product Strat. | Payment of exercise price or tax liability using portion of securities received from the company at price $ 142.54 per share. | 10 Feb 2025 | 445 | 8,553 (0%) | 0% | 142.5 | 63,430 | Common Stock |
| Biogen Inc | Rachid Izzar | Head of Global Product Strat. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Feb 2025 | 2,043 | 2,044 | - | - | Restricted Stock Unit | |
| Biogen Inc | Rachid Izzar | Head of Global Product Strat. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Feb 2025 | 2,043 | 7,224 (0%) | 0% | 0 | Common Stock | |
| Biogen Inc | Rachid Izzar | Head of Global Product Strat. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Feb 2025 | 1,801 | 7,860 (0%) | 0% | 0 | Common Stock | |
| Biogen Inc | Rachid Izzar | Head of Global Product Strat. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Feb 2025 | 1,801 | 3,604 | - | - | Restricted Stock Unit | |
| Biogen Inc | Rachid Izzar | Head of Global Product Strat. | Payment of exercise price or tax liability using portion of securities received from the company at price $ 141.35 per share. | 07 Feb 2025 | 600 | 6,624 (0%) | 0% | 141.4 | 84,810 | Common Stock |
| Biogen Inc | Rachid Izzar | Head of Global Product Strat. | Payment of exercise price or tax liability using portion of securities received from the company at price $ 141.35 per share. | 07 Feb 2025 | 565 | 6,059 (0%) | 0% | 141.4 | 79,863 | Common Stock |
| Biogen Inc | Rachid Izzar | Head of Global Product Strat. | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Feb 2025 | 9,130 | 9,130 | - | - | Restricted Stock Unit | |
| Biogen Inc | Izzar Rachid | Head of Global Product Strat. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Feb 2024 | 1,370 | 0 | - | - | Performance Stock Unit | |
| Biogen Inc | Izzar Rachid | Head of Global Product Strat. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Feb 2024 | 1,370 | 10,006 (0%) | 0% | 0 | Common Stock | |
| Biogen Inc | Rachid Izzar | Head of Global Product Strat. | Other type of transaction at price $ 0.00 per share. | 16 Feb 2024 | 807 | 0 | - | - | Restricted Stock Unit | |
| Biogen Inc | Izzar Rachid | Head of Global Product Strat. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Feb 2024 | 647 | 807 | - | - | Restricted Stock Unit | |
| Biogen Inc | Izzar Rachid | Head of Global Product Strat. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Feb 2024 | 647 | 10,014 (0%) | 0% | 0 | Common Stock | |
| Biogen Inc | Izzar Rachid | Head of Global Product Strat. | Payment of exercise price or tax liability using portion of securities received from the company at price $ 219.08 per share. | 16 Feb 2024 | 639 | 9,367 (0%) | 0% | 219.1 | 139,992 | Common Stock |
| Biogen Inc | Rachid Izzar | Head of Global Product Strat. | Payment of exercise price or tax liability using portion of securities received from the company at price $ 219.08 per share. | 16 Feb 2024 | 313 | 9,701 (0%) | 0% | 219.1 | 68,572 | Common Stock |
| Biogen Inc | Rachid Izzar | Head of Global Product Strat. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Feb 2024 | 1,515 | 9,081 (0%) | 0% | 0 | Common Stock | |
| Biogen Inc | Rachid Izzar | Head of Global Product Strat. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Feb 2024 | 1,515 | 1,515 | - | - | Restricted Stock Unit | |
| Biogen Inc | Izzar Rachid | Head of Global Product Strat. | Payment of exercise price or tax liability using portion of securities received from the company at price $ 240.98 per share. | 09 Feb 2024 | 445 | 8,636 (0%) | 0% | 241.0 | 107,236 | Common Stock |
| Biogen Inc | Izzar Rachid | Head of Global Product Strat. | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Feb 2024 | 5,405 | 5,405 | - | - | Restricted Stock Unit | |
| Biogen Inc | Izzar Rachid | Head of Global Product Strat. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Feb 2024 | 2,043 | 4,087 | - | - | Restricted Stock Unit | |
| Biogen Inc | Rachid Izzar | Head of Global Product Strat. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Feb 2024 | 2,043 | 8,187 (0%) | 0% | 0 | Common Stock | |
| Biogen Inc | Rachid Izzar | Head of Global Product Strat. | Payment of exercise price or tax liability using portion of securities received from the company at price $ 240.30 per share. | 07 Feb 2024 | 621 | 7,566 (0%) | 0% | 240.3 | 149,226 | Common Stock |
| Biogen Inc | Rachid Izzar | Head of Global Product Strat. | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Jan 2024 | 1,370 | 1,370 | - | - | Performance Stock Unit | |
| Biogen Inc | Rachid Izzar | Head of Global Product Strat. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jun 2023 | 504 | 6,388 (0%) | 0% | 0 | Common Stock | |
| Biogen Inc | Rachid Izzar | Head of Global Product Strat. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jun 2023 | 504 | 0 | - | - | Restricted Stock Unit | |
| Biogen Inc | Rachid Izzar | Head of Global Product Strat. | Payment of exercise price or tax liability using portion of securities received from the company at price $ 284.85 per share. | 30 Jun 2023 | 244 | 6,144 (0%) | 0% | 284.8 | 69,503 | Common Stock |
| Biogen Inc | Rachid Izzar | Head of Global Product Strat. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Feb 2023 | 767 | 2,135 | - | - | Restricted Stock Unit | |
| Biogen Inc | Rachid Izzar | Head of Global Product Strat. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Feb 2023 | 767 | 5,884 (0%) | 0% | 0 | Common Stock | |
| Biogen Inc | Rachid Izzar | Head of Global Product Strat. | Other type of transaction at price $ 0.00 per share. | 17 Feb 2023 | 681 | 1,454 | - | - | Restricted Stock Unit | |
| Biogen Inc | Rachid Izzar | Head of Global Product Strat. | Payment of exercise price or tax liability using portion of securities received from the company at price $ 278.38 per share. | 17 Feb 2023 | 371 | 5,117 (0%) | 0% | 278.4 | 103,279 | Common Stock |
| Biogen Inc | Rachid Izzar | Head of Global Product Strat. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Feb 2023 | 1,515 | 6,359 (0%) | 0% | 0 | Common Stock | |
| Biogen Inc | Rachid Izzar | Head of Global Product Strat. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Feb 2023 | 1,515 | 3,030 | - | - | Restricted Stock Unit | |
| Biogen Inc | Rachid Izzar | Head of Global Product Strat. | Payment of exercise price or tax liability using portion of securities received from the company at price $ 286.30 per share. | 10 Feb 2023 | 642 | 5,488 (0%) | 0% | 286.3 | 183,805 | Common Stock |
| Biogen Inc | Rachid Izzar | Head of Global Product Strat. | Other type of transaction at price $ 0.00 per share. | 10 Feb 2023 | 553 | 0 | - | - | Restricted Stock Unit | |
| Biogen Inc | Rachid Izzar | Head of Global Product Strat. | Payment of exercise price or tax liability using portion of securities received from the company at price $ 286.30 per share. | 10 Feb 2023 | 462 | 5,897 (0%) | 0% | 286.3 | 132,271 | Common Stock |
| Biogen Inc | Rachid Izzar | Head of Global Product Strat. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Feb 2023 | 453 | 6,350 (0%) | 0% | 0 | Common Stock | |
| Biogen Inc | Rachid Izzar | Head of Global Product Strat. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Feb 2023 | 453 | 553 | - | - | Restricted Stock Unit | |
| Biogen Inc | Rachid Izzar | Head of Global Product Strat. | Payment of exercise price or tax liability using portion of securities received from the company at price $ 286.30 per share. | 10 Feb 2023 | 220 | 6,130 (0%) | 0% | 286.3 | 62,986 | Common Stock |
| Biogen Inc | Rachid Izzar | Head of Global Product Strat. | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Feb 2023 | 6,130 | 6,130 | - | - | Restricted Stock Unit | |
| Biogen Inc | Rachid Izzar | Head of Alzheimers Disease | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jan 2023 | 1,783 | 4,844 (0%) | 0% | 0 | Common Stock | |
| Biogen Inc | Rachid Izzar | Head of Alzheimers Disease | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Dec 2022 | 1,285 | 3,395 (0%) | 0% | 0 | Common Stock | |
| Biogen Inc | Rachid Izzar | Head of Alzheimers Disease | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Dec 2022 | 1,285 | 0 | - | - | Restricted Stock Unit | |
| Biogen Inc | Rachid Izzar | Head of Alzheimers Disease | Payment of exercise price or tax liability using portion of securities received from the company at price $ 298.90 per share. | 02 Dec 2022 | 570 | 2,825 (0%) | 0% | 298.9 | 170,373 | Common Stock |
| Biogen Inc | Rachid Izzar | Head of Alzheimers Disease | Other type of transaction at price $ 0.00 per share. | 02 Dec 2022 | 433 | 0 | - | - | Restricted Stock Unit | |
| Biogen Inc | Rachid Izzar | Head of Alzheimers Disease | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Dec 2022 | 425 | 3,250 (0%) | 0% | 0 | Common Stock | |
| Biogen Inc | Rachid Izzar | Head of Alzheimers Disease | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Dec 2022 | 425 | 433 | - | - | Restricted Stock Unit | |
| Biogen Inc | Rachid Izzar | Head of Alzheimers Disease | Payment of exercise price or tax liability using portion of securities received from the company at price $ 298.90 per share. | 02 Dec 2022 | 189 | 3,061 (0%) | 0% | 298.9 | 56,492 | Common Stock |
| Biogen Inc | Rachid Izzar | Head of Alzheimers Disease | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jul 2022 | 504 | 504 | - | - | Restricted Stock Unit | |
| Biogen Inc | Rachid Izzar | Head of Alzheimers Disease | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jul 2022 | 504 | 2,258 (0%) | 0% | 0 | Common Stock | |
| Biogen Inc | Rachid Izzar | Head of Alzheimers Disease | Payment of exercise price or tax liability using portion of securities received from the company at price $ 210.63 per share. | 01 Jul 2022 | 148 | 2,110 (0%) | 0% | 210.6 | 31,173 | Common Stock |
| Biogen Inc | Rachid Izzar | Head of Alzheimers Disease | Other type of transaction at price $ 0.00 per share. | 18 Feb 2022 | 854 | 2,902 | - | - | Restricted Stock Unit | |
| Biogen Inc | Rachid Izzar | Head of Alzheimers Disease | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Feb 2022 | 594 | 1,929 (0%) | 0% | 0 | Common Stock | |
| Biogen Inc | Rachid Izzar | Head of Alzheimers Disease | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Feb 2022 | 594 | 3,756 | - | - | Restricted Stock Unit | |
| Biogen Inc | Rachid Izzar | Head of Alzheimers Disease | Payment of exercise price or tax liability using portion of securities received from the company at price $ 209.79 per share. | 18 Feb 2022 | 175 | 1,754 (0%) | 0% | 209.8 | 36,713 | Common Stock |
| Biogen Inc | Rachid Izzar | Head of Alzheimers Disease | Other type of transaction at price $ 0.00 per share. | 12 Feb 2022 | 651 | 1,006 | - | - | Restricted Stock Unit | |
| Biogen Inc | Rachid Izzar | Head of Alzheimers Disease | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Feb 2022 | 351 | 1,457 (0%) | 0% | 0 | Common Stock | |
| Biogen Inc | Rachid Izzar | Head of Alzheimers Disease | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Feb 2022 | 351 | 1,657 | - | - | Restricted Stock Unit | |
| Biogen Inc | Rachid Izzar | Head of Alzheimers Disease | Payment of exercise price or tax liability using portion of securities received from the company at price $ 214.59 per share. | 12 Feb 2022 | 122 | 1,335 (0%) | 0% | 214.6 | 26,180 | Common Stock |
| Biogen Inc | Rachid Izzar | Head of Alzheimers Disease | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Feb 2022 | 4,545 | 4,545 | - | - | Restricted Stock Unit | |
| Biogen Inc | Rachid Izzar | Head of Alzheimers Disease | Other type of transaction at price $ 0.00 per share. | 02 Dec 2021 | 484 | 858 | - | - | Restricted Stock Unit | |
| Biogen Inc | Rachid Izzar | Head of Alzheimers Disease | Exercise or conversion of derivative security received from the company (such as an option) at price $ 228.52 per share. | 02 Dec 2021 | 372 | 1,271 (0%) | 0% | 228.5 | 85,009 | Common Stock |
| Biogen Inc | Rachid Izzar | Head of Alzheimers Disease | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Dec 2021 | 372 | 1,342 | - | - | Restricted Stock Unit | |
| Biogen Inc | Rachid Izzar | Head of Alzheimers Disease | Payment of exercise price or tax liability using portion of securities received from the company at price $ 228.52 per share. | 02 Dec 2021 | 165 | 1,106 (0%) | 0% | 228.5 | 37,706 | Common Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges